Inhibikase Therapeutics, Inc. 8-K

What Happened
Inhibikase Therapeutics, Inc. (IKT) announced on July 29, 2026 that it entered into an exchange agreement with RA Capital Healthcare Fund, L.P. Under the agreement, RA Capital exchanged 18,030,000 shares of IKT common stock for a pre-funded warrant to acquire 18,030,000 shares of common stock. The pre-funded warrant carries a $0.001 exercise price per share, is immediately exercisable, has no expiration date, and includes customary adjustment provisions for stock splits and similar corporate events.

Key Details

• Transaction date: July 29, 2026; counterparty: RA Capital Healthcare Fund, L.P.
• Shares exchanged: 18,030,000 common shares for a pre-funded warrant to acquire 18,030,000 shares.
• Warrant terms: $0.001 exercise price, immediately exercisable, no expiration; issuable shares subject to adjustment for splits/dividends.
• Beneficial ownership blocker: holder may not exercise if doing so would cause beneficial ownership to exceed 9.99% of outstanding shares (holder may adjust this threshold, with 61 days’ prior notice, up to 19.99%).
• Securities issued without registration under the exemption in Section 3(a)(9) of the Securities Act.

Why It Matters
This exchange swaps outstanding shares for a pre-funded warrant rather than raising cash for the company. Because the warrant is immediately exercisable and has no expiration, it represents potential future dilution if exercised; however, the beneficial ownership blocker limits RA Capital’s ability to convert into a large ownership stake immediately. Investors should note the change in instrument type (shares → warrant), the near-zero exercise price, and that future exercises could increase the company’s outstanding share count subject to the blocker and any adjustments for corporate actions.